Primary systemic therapy for operable breast cancer - 10 year survival data after chemotherapy and hormone therapy
1997

Long-term Survival Data After Preoperative Therapy for Breast Cancer

Sample size: 94 publication Evidence: moderate

Author Information

Author(s): DA Cameron, EDC Anderson, P Levack, RA Hawkins, TJ Anderson, RCF Leonard, APM Forrest, U Chetty

Primary Institution: University Departments of Surgery and Medical Oncology, Western General Hospital, Edinburgh

Hypothesis

Can preoperative systemic therapy improve survival in women with operable breast cancer?

Conclusion

The study found no difference in survival between women given initial hormone therapy and those given chemotherapy, but identified axillary node involvement as a key predictor of poor survival.

Supporting Evidence

  • Overall survival was 55% at 10 years, with the median survival not yet reached.
  • Patients with no involved axillary nodes had a better prognosis compared to those with involved nodes.
  • Response to primary chemotherapy was 70%, while hormone therapy had a 40% response rate.

Takeaway

This study looked at women with breast cancer and found that the type of treatment they received before surgery didn't change their chances of living longer, but how many lymph nodes were affected did matter.

Methodology

The study involved 94 women with operable breast cancer who received either hormone therapy or chemotherapy before surgery, with follow-up data collected over a median of 7.5 years.

Limitations

The study did not allow for full knowledge of the patients' preoperative axillary nodal status, which may affect the interpretation of results.

Participant Demographics

Median age of participants was 53 years, with a range from 33 to 72 years.

Statistical Information

P-Value

p<0.00001

Statistical Significance

p<0.00001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication